AstraZeneca strikes global collaboration and licence agreement with Neurimmune
1st Mar 2022 07:51
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its rare diseases subsidiary had closed an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development.
Read moreAstraZeneca chair to step down next year
22nd Feb 2022 12:21
(Sharecast News) - AstraZeneca chair Leif Johansson is to retire next year, it was announced on Tuesday, taking his time in the role to over a decade.
Read moreAstraZeneca's Enhertu demonstrates 'statistically significant' survival rates in patients with breast cancer
21st Feb 2022 07:06
(Sharecast News) - Drugmaker AstraZeneca said its Enhurtu breast cancer drug had demonstrated a "statistically significant and clinically meaningful improvement" in survival a phase three trial versus chemotherapy.
Read moreAstraZeneca's Saphnelo receives EU approval
16th Feb 2022 07:10
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that Saphnelo had received European Union approval as an add-on therapy for the treatment of adult patients with moderate-to-severe, active autoantibody-positive systemic lupus erythematosus.
Read moreAstraZeneca's Lynparza delays progression risk in prostate cancer
15th Feb 2022 07:42
(Sharecast News) - Pharmaceutical company AstraZeneca said on Tuesday that results from a recent study revealed that its Lynparza asset reduced the risk of first-line metastatic castration-resistant prostate cancer progression by 34% when used in combination with abiraterone.
Read moreAstraZeneca raises dividend on growth prospects
10th Feb 2022 07:04
(Sharecast News) - AstraZeneca announced the first increase to its dividend for a decade and an upbeat outlook as the drugs company swung to a fourth-quarter loss driven by higher costs.
Read moreThursday preview: US CPI, AstraZeneca in focus
9th Feb 2022 18:32
(Sharecast News) - Investors' attention will be firmly on the latest consumer price due out in the US covering the month of January.
Read moreImmune system creates neutralising antibodies against Omicron after three exposures
7th Feb 2022 15:26
(Sharecast News) - German scientists have shown that the human immune system creates an abundant amount of high quality antibodies capable of neutralising Omicron once it has encountered the virus's spike protein three times.
Read moreSpanish Covid-19 vaccine shows high efficacy against Omicron variants
1st Feb 2022 13:22
(Sharecast News) - The Covid-19 vaccine being developed by Spain's Hipra has shown a "high efficacy" against the new Omicron variants and is now entering third phase clinical trials.
Read moreOmicron subvariant is 1.5 times more transmissible than original
31st Jan 2022 10:58
(Sharecast News) - A new Omicron subvariant known is more transmissible than its forebear which first appeared in South Africa, scientists said at the weekend, although some studies have shown that vaccines are more effective against it.
Read moreMorgan Stanley reiterates 'buy' for FTSE 100, highlights 'defensive' qualities
24th Jan 2022 12:13
(Sharecast News) - Analysts at Morgan Stanley sounded a 'bullish' note on the outlook for the FTSE 100, highlighting its greater 'defensive' properties relative to rivals, higher dividend yields versus global peers, exposure to energy and record low expectations for growth in the profits of its constituent companies.
Read moreAstraZeneca reports positive results from Imfinzi trials
19th Jan 2022 07:55
(Sharecast News) - AstraZeneca on Wednesday said its Imfinzi drug combined with chemotherapy reduced the risk of death by 20% in people with advanced biliary tract cancer (BTC) after results from a phase III clinical trial.
Read moreAstraZeneca's Enhertu granted priority review by US FDA
17th Jan 2022 07:38
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Daiichi Sankyo collaboration Enhertu had been granted priority review by the Federal Drug Administration in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.
Read moreAstraZeneca strikes collaboration and license agreement with Neurimmune
7th Jan 2022 07:07
(Sharecast News) - Drugmaker AstraZeneca's Alexion rare diseases unit has inked an exclusive collaboration and license agreement with Neurimmune that will see the pair develop and commercialise NI006, an investigational human monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy.
Read moreAstraZeneca, Ionis close eplontersen deal
29th Dec 2021 07:34
(Sharecast News) - AstraZeneca said on Wednesday that it has closed a global development and commercialisation agreement with California-based Ionis Pharmaceutical for eplontersen, a medicine used in the treatment of transthyretin amyloidosis.
Read more